Literature DB >> 17594347

Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art.

Andrew V Schally1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17594347     DOI： 10.1111/j.1464-410X.2007.06942.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  2 in total

1.  Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.

Authors:  S Hori; T Jabbar; N Kachroo; J C Vasconcelos; C N Robson; V J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2011-02       Impact factor: 4.553

2.  An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.

Authors:  Ferenc G Rick; Norman L Block; Andrew V Schally
Journal:  Onco Targets Ther       Date:  2013-04-16       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.